Shares of Meridian Biosciences (VIVO) were moving steadily higher in early trading on 4/28 after the company announced its Q2 2016 earnings of 24 cents per share and revenues of $51.3 million.   Estimates were for 24 cents per share in earnings and $52.09 million in revenues for the quarter.   The company affirmed its full year guidance.

Meridian specializes in rapid results laboratory testing for infectious diseases, and could be a key player in the Zika virus dynamic.   Most recently Meridian introduced an improved version of its Illumigene testing system for Mycloplasma  pneumoniae , a bacteria that causes a significant number of respiratory illnesses. The new generation testing kit works faster and is easily performed without specific training or reagents, a fact that is expected to increase the market share for the Illumigene line.  

Meridian has a nifty 3.86% dividend yield with an 80 cent per year payout to its stockholders.   

Meridian Biosciences (VIVO) is a up to buy $23. 

Disclosure: I own shares in Meridian Biosciences.